Governance for Medical Information Content Review and Updates Governance for Medical Information Content Review and Updates Context In the pharmaceutical industry, the dissemination of medical information is critical for ensuring that healthcare professionals receive accurate and clinically relevant content. The regulatory framework governing the promotion of pharmaceuticals is complex and varies by jurisdiction. Regulatory Affairs (RA) professionals play a significant role in ensuring that medical information complies with regional and international guidelines. This article aims to provide an in-depth understanding of the governance surrounding medical information content review and updates, focusing on key regulations, agency expectations, and potential pitfalls that…

Metrics That Show the Volume and Nature of Off-Label Queries Metrics That Show the Volume and Nature of Off-Label Queries In the ever-evolving landscape of pharmaceuticals, regulatory affairs professionals must grapple with the complexities of off-label communications. The intersection of pharmacovigilance solutions and promotional compliance presents challenges that necessitate a thorough understanding of global regulatory guidelines, particularly in the US, UK, and EU. This article aims to delineate the relevant regulations, agency expectations, key performance metrics, and documentation strategies regarding off-label queries. Context Off-label use refers to the utilization of a pharmaceutical product in a manner not specified in the…

Handling Off-Label Discussions in Advisory Boards and Scientific Meetings Handling Off-Label Discussions in Advisory Boards and Scientific Meetings In the field of pharmaceutical regulatory affairs and compliance, managing off-label discussions during advisory boards and scientific meetings is a critical area requiring careful attention to legal and ethical guidelines. This article provides a comprehensive overview of the relevant regulations, guidelines, and agency expectations surrounding this topic, tailored specifically for regulatory affairs, CMC, and labelling teams in the US, UK, and EU. Context Off-label use refers to the prescribing of pharmaceutical products for indications not approved by regulatory agencies. While this practice…

Use of Real-World Evidence in Medical Responses Without Crossing Lines Use of Real-World Evidence in Medical Responses Without Crossing Lines In recent years, the pharmaceutical and biotechnology industries have increasingly harnessed real-world evidence (RWE) to support medical responses and compliance efforts. However, the utilization of RWE subject to strict regulations and guidance is paramount to ensure adherence to compliance regulatory affairs. This article acts as a comprehensive guide for regulatory affairs professionals, detailing the pertinent guidelines, agency expectations, and interaction with various functions within the organization concerning RWE in medical communications. Regulatory Context Understanding how to navigate the complex landscape…

Aligning Medical Information Outputs with Core Data Sheets and Labels Aligning Medical Information Outputs with Core Data Sheets and Labels Context The pharmaceutical industry operates under stringent regulations regarding the dissemination of medical information and promotional materials. This is essential not only for compliance but also for maintaining public trust and ensuring patient safety. Regulatory affairs compliance is critical in aligning medical information outputs with core data sheets and product labels. This article explores the frameworks and guidelines applicable within the US, UK, and EU, underscoring the importance of adhering to regulatory expectations and best practices in medical communications governance….

Audits of Medical Information: What Inspectors and Internal QA Look For Audits of Medical Information: What Inspectors and Internal QA Look For In the pharmaceutical and biotechnology sectors, the landscape of regulatory affairs is complex and constantly evolving. One significant aspect of this is the management of medical information and adherence to promotional compliance. This article serves as an in-depth regulatory explainer manual on the audits of medical information, focusing on the expectations from inspectors and internal Quality Assurance (QA) teams. We will explore the relevant guidelines, regulations, documentation requirements, review processes, common deficiencies, and best practices for Regulatory Affairs…

Designing Escalation Pathways for High-Risk or Sensitive Questions Designing Escalation Pathways for High-Risk or Sensitive Questions In the dynamic landscape of the pharmaceutical and biotech industry, the need to establish effective escalation pathways for handling high-risk or sensitive questions has become increasingly paramount. This necessity is further underscored by the regulatory expectations surrounding pharmacovigilance, advertising compliance, and medical information governance. This manual aims to provide a comprehensive overview of the regulations, guidelines, and best practices that govern the management of such inquiries, particularly within the context of US, UK, and EU regulatory frameworks. Context Effective management of high-risk or sensitive…

Managing Requests from Payers, HTA Bodies and Policy Stakeholders Managing Requests from Payers, HTA Bodies and Policy Stakeholders Context The pharmaceutical and biotechnology industries operate under stringent regulatory frameworks designed to ensure the safety and efficacy of medicines. Central to regulatory affairs (RA) is managing requests from various stakeholders, including payers, health technology assessment (HTA) bodies, and policy stakeholders. This article delves into the intricacies of these interactions, the relevant global regulations, and best practices for compliance, particularly as they relate to iqvia pharmacovigilance and medical communications. Understanding how to navigate these requests is essential for professionals in Regulatory Affairs,…

Using Insights from Medical Information to Inform Safety and Strategy Using Insights from Medical Information to Inform Safety and Strategy In the ever-evolving landscape of pharmaceutical advertising and promotion, regulatory compliance necessitates a comprehensive understanding of off-label requests and medical information controls. This article provides a structured regulatory explainer manual to guide professionals in the pharmaceutical and biotech industry on efficiently managing medical information while aligning with global regulatory expectations, particularly in the US, UK, and EU. Regulatory Affairs Context Regulatory Affairs (RA) professionals play a pivotal role in ensuring that all aspects of a pharmaceutical product marketed in the…

Ensuring Consistency Between Medical Information, Publications and Promotion Ensuring Consistency Between Medical Information, Publications and Promotion Context of Regulatory Affairs in Medical Communications In the pharmaceutical and biotech industries, the intersection of medical information, publications, and promotional materials is governed by a complex web of regulations and guidelines. Regulatory Affairs (RA) professionals must ensure that all communication surrounding medical products is accurate, transparent, and compliant with applicable legal frameworks. This article focuses on the delicate balance of ensuring consistency across various channels of medical communication, specifically related to ai medical writing, pharmaceutical advertising compliance, and medical communications governance. Legal and…